Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million ~

John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics

Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit

Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

Kymab granted leave to appeal to the UK Supreme Court

Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting

Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)

Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech

Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results

Novan Announces Corporate Update Conference Call and Webcast

Melinta Therapeutics Reports Third Quarter 2018 Financial Results

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101

Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors

Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP

Novan Creates Dedicated Women’s Health Business Unit

Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer

Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan

Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program

Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries

Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November

Novan Receives FDA Guidance for SB204 and Acne Indication

Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam)

Melinta Therapeutics Names Peter Milligan as Chief Financial Officer

Mycovia Pharmaceuticals Debuts with Initiation of Phase 3 Clinical Trials for Treatment of Recurrent Vulvovaginal Candidiasis

Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference

Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

Immunocore strengthens IP position in the field of TCR-based therapeutics

Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018

Novan Announces Promising Clinical Results with SB414

Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours

Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract

Melinta Therapeutics Reports Second Quarter 2018 Financial Results

Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies

Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases

Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer

Poseida Therapeutics Appoints John P. Schmid to Board of Directors

Immunocore Management Change

New IMCgp100-102 Data Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma

Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock

Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

Melinta Therapeutics Announces Pricing of Public Offering of Common Stock

Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting

Melinta Therapeutics Announces Proposed Offering of Common Stock

SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment

Novan Provides Update on SB414 Inflammatory Skin Disease Development Program

Melinta Therapeutics Reports First Quarter 2018 Financial Results

Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria

Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018

Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA

Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations

Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018

Altan Pharma Announces the Grant of Two Patents by the USPTO

Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018

Novan Advances Organization and Strengthens Leadership Team

Poseida Raises $30.5 Million in Series B Financing

Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018

Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe

Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference

Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer

Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018

Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ in Patients with cUTI

Dr. Eugene Sun Appointed to Novan Board of Directors

Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina

Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies

Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne

Immunocore Announces Leadership Change

Novoclem announces CEO Anne Whitaker to present at the BIO CEO & Investor Annual Conference on Monday February 12th, 2018

Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations

Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States

Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206

Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis

Xenex LightStrike Germ-Zapping Robots Helping Stanford Health Care – ValleyCare Destroy Germs and Bacteria

Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference

Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio

Novan Announces Pricing of $38.0 Million Offering of Common Stock and Warrants

Novoclem announces CEO Anne Whitaker to present at the Biotech Showcase™ Annual Conference on Wednesday, January 10, 2018

Novan Announces Proposed Public Offering of Common Stock and Warrants

Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors

Novoclem announces issuance of patent covering a core technology underlying its Cystic Fibrosis therapeutic development program

NovaQuest Capital Management to Acquire Viamet Pharmaceuticals and the VT-1161 Antifungal Program

Ochsner Medical Center Reports 49% Decrease in Infection Rates After Germ-Fighting Robots Deployed to Disinfect Patient Rooms

Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma

Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma

Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting

Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting

Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414

Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company

Novan to Present at Piper Jaffray 29th Annual Healthcare Conference

New Study Proves 2-Minute Cycle with Pulsed Xenon UV Significantly Reduces OR Contamination

Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit

Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne

Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate

Kymab to present data on its lead immuno-oncology antibody, demonstrating strong potential for inhibiting tumour growth

Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Novoclem Therapeutics Receives QIDP Status for Its Lead Inhaled Antimicrobial Drug Candidate

Novan Announces Plan to Complete Development of SB204 Acne Candidate via Third Party Funding and Execution

Melinta Therapeutics Announces Successful Completion of Merger

Novoclem Presents Promising New Data At The North America Cystic Fibrosis Conference on November 2, 2017

Poseida Therapeutics’ CAR-T Programs to be Featured in Three Presentations at American Society of Hematology 2017 Annual Meeting

Melinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization

Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company

Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States

Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma

KNOW Bio Strengthens Leadership With The Addition Of Four New Board Members

Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities

Viamet to Present Data Demonstrating the Efficacy and Safety of VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis at ISIDOG Congress 2017

Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide

Novan Announces Corporate Update Conference Call and Webcast

Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne

Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat

New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek

Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer

Cempra and Melinta Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger

Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma

Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries via Extended Agreement with Eurofarma Laboratórios

Machelle Sanders Appointed to Novan Board of Directors

Novan Conducts Guidance Meeting with FDA on SB204 Development Program

Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections

Melinta Therapeutics to Participate in Two Upcoming Investor Conferences

Kymab and Seattle Children’s Research Institute publish impressive results using Kymab’s KY1005 in a model of Acute Graft versus Host Disease (aGVHD) in Science Translational Medicine

Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens

Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases

Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit

Novan Appoints Paula Brown Stafford, Chief Development Officer, to Board of Directors

Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting

Cempra and Melinta Announce Merger to Form Leading, Vertically Integrated Commercial-Stage Anti-Infectives Company

Data on Viamet’s VT-1161 for Treatment of RVVC to be Presented at IDSOG Annual Meeting

Kymab Announces Clinical Update on its promising new antibody KY1005 for treatment of autoimmune diseases

Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the APMA Annual Meeting

Novan Announces Corporate Update Conference Call and Webcast

FDA Grants Fast Track Designation to VT-1598 for Treatment of Valley Fever

Surgical Specialty Center of Baton Rouge is First Hospital in Southern Louisiana to Enhance Patient Safety by Deploying a Xenex LightStrike Germ-Zapping Robot

Novan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology

Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK

Immunocore announces third oncology target selected in discovery collaboration with GlaxoSmithKline

Melinta Signs $90 Million Financing Agreement with Oberland Capital to Fund Baxdela™ Commercial Activities and Expansion into Additional Indications

Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the 4th International Summit on Nail Diseases

Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Kymab appoints Dr Martin Nicklasson as Non-Executive Chair

Viamet to Participate in Antifungal Panel Discussion at the 2017 BIO International Convention

Xenex Announces LightStrike Disinfection Pod™ – Industry’s First Mobile Equipment Disinfection System

3D4Medical announces exclusive partnership with Sky

Melinta Therapeutics Demonstrates Potential of Pyrrolocytosine Candidate against Gonorrhea

Novan Announces Leadership Adjustments and Business Update

Viamet’s VT-1598 Demonstrates Potent Activity Against Candida auris and Other Life-Threatening Fungal Species

Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting

Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting

Viamet Presents Phase 2b Results Demonstrating Unprecedented Efficacy of Oral VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis

Melinta Therapeutics Presenting In Vivo and In Vitro Results from Baxdela Studies at ASM Microbe

Immunocore Highlights IMCgp100 clinical data in Uveal Melanoma at ASCO 2017 Annual Meeting

Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy

Viamet Data for VT-1161 and VT-1598 to be Presented at The American Society for Microbiology’s ASM Microbe 2017 Conference

Novan Reports First Quarter 2017 Financial Results

Abbas Hussain Joins the Board of Immunocore as Non-Executive Director

3D4Medical Launches Complete Ortho – its Latest Clinical App for iPhone and iPad

Kymab appoints Dr Sonia Quaratino as Chief Medical Officer

Immunocore identifies second novel ImmTAC® in the GSK collaboration

Melinta Therapeutics’ Phase 3 trials of Baxdela Document Challenges in Antibiotic Selection in Patients Treated for ABSSSI

Novan Presents Safety Data for SB204 Program

Novan Presents Preclinical Data from Inflammatory Skin Diseases Program

Melinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug Design

Melinta Therapeutics Presentations at ECCMID Show Potential of Baxdela in Obese and other Challenging Patient Types

Melinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017

Novan Reports Positive Topline Results with SB208 in Phase 2 Trial

Novan Welcomes Key Opinion Leaders to New Advisory Council

Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at AACR

3D4Medical announces the appointment of top medical professionals to its Medical Advisory Board

Xenex Announces New 2-Minute Run-Time for OR Disinfection with LightStrike Germ-Zapping Robots™ at AORN Surgical Conference & Expo

Henry Ford and HonorHealth are First Health Systems to Deploy Xenex LightStrike Germ-Zapping Robots Across All Hospitals

Novan Reshapes Executive Management Team

Novan Reports Fourth Quarter and Full Year 2016 Financial Results

Viamet Presents Positive Results from Phase 2b Trial of VT-1161 in Onychomycosis at AAD

Novan Provides Update on SB204 Development Program

Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries

Novan’s Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting

Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference

Viamet Announces RENOVATE Phase 2b Onychomycosis Results to be Presented at the AAD 2017 Annual Meeting

Immunocore to Present at the Cowen and Company 37th Annual Healthcare Conference

Melinta Announces FDA Acceptance of Investigational New Drug Application for Topical Radezolid

Melinta Therapeutics Provides Baxdela NDA Update

Xenex Secures $38 Million in Funding Led by Essex Woodlands & Piper Jaffray Merchant Banking

3D4Medical Announces the Appointment of Top Academics to Its Academic Review Board

Xenex LightStrike Germ-Zapping Robots Battling Superbugs in UK; Infection Prevention & Control Conference Will Feature Pulsed Xenon Light Disinfection Technology

Novan Reports Topline Results from SB204 Phase 3 Pivotal Trials

Anne Whitaker Named CEO of KNOW Bio Respiratory Company

Kymab appoints Dr Arndt Schottelius as Executive Vice President Research & Development

Novan Licenses SB204 to Sato for Acne in Japan

Kymab Expands Infectious Disease Programmes

Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis

Viamet Reports Positive Results from RENOVATE Phase 2b Trial of Oral VT-1161 in Onychomycosis

Terumo Chooses Xenex LightStrike Germ-Zapping Robots to Disinfect Healthcare Facilities & Improve Patient Safety in Japan

Melinta Therapeutics’ New Drug Application for Baxdela Accepted for Filing by US FDA

Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs

Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at ASH

Kymab new therapeutic antibody for autoimmune diseases shows potential for improvement in post-transplant survival

Immunocore wins Financing Deal of the Year at the 12th Annual SCRIP Awards 2016

Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206

Kymab secures US$100 million Series C funding

Novan Announces Preclinical Data Demonstrating Immunomodulatory Effect In Vivo

Novan Reports Third Quarter 2016 Financial Results

Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at SMR 2016 Congress

Viamet Pharmaceuticals Announces Presentations at ID Week 2016 on Novel Antifungal Compounds VT-1161 and VT-1129

Melinta Therapeutics’ Baxdela™ to be Featured in Six Poster Presentations at IDWeek 2016™

Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections

Novan to Present Data from SB204 Phase 2b Trial at Fall Clinical Dermatology Conference

FDA Grants QIDP and Fast Track Designations to VT-1161 for Treatment of RVVC

Immunocore Appoints Paul Fry as Chief Financial Officer

Kymab and EpimAb Biotherapeutics Announce Multi-Target, Bispecific Antibody Cross-Licensing Agreement

Novan Announces Both Phase 3 Pivotal Trials for SB204 Fully Enrolled

Viamet to Present at the 25th European Academy of Dermatology and Venereology Congress

Viamet to Present at the 2016 Mycoses Study Group Education and Research Consortium Conference

FDA Grants QIDP Designation to VT-1598 for Treatment of Valley Fever

Phoenix VA Health Care System Deploys Germ-Zapping Robots to Enhance Veteran Safety

Life Line Hospital is the First Long Term Acute Care Hospital in Ohio to Enhance Patient Safety by Deploying a Xenex Germ-Zapping Robot

Kymouse™ successfully demonstrates steps to developing HIV vaccine

Poseida Therapeutics Establishes Scientific Advisory Board

3D4Medical Launches Lecture Builder, Transforming Anatomy Education

Award-winning medical platform ‘Complete Anatomy’ now available for Mac desktops and notebooks

Poseida Therapeutics Expands Executive Leadership Team

Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting

Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program

Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting

Melinta Therapeutics Presenting Results from Baxdela and ESKAPE Programs at ASM Microbe 2016 Meeting

3D4Medical receives Prestigious Apple Design Award

Immunocore’s ImmTAV Shown to Redirect the Immune System to Kill HIV-Infected Cells from Patients Treated with Antiretroviral Therapy

Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting

Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis

Xenex Germ-zapping Robot Kills CRE; Robot Destroys Nightmare Bacteria Like CRE, Ebola & C.diff Before They Make People Sick

Viamet Receives Orphan Drug Designation from the FDA for VT-1598 for the Treatment of Coccidioidomycosis

Vidant Edgecombe Deploys Xenex Germ-Zapping Robot

Germ wars: The robots strike back

Melinta Therapeutics’ Baxdela™ Successfully Achieves Endpoints in Confirmatory Phase 3 Study in Patients with Hospital-Treated Skin Infections

Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206

Springfield Clinic Unveils Xenex Germ-Zapping Robot

Melinta Therapeutics Appoints Dr. Eugene Sun as Chief Executive Officer

Kymab and Heptares enter strategic collaboration to discover, develop and commercialise novel antibody therapeutics

Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma

Kymab appoints Dr David Chiswell as Chief Executive Officer

Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis

LightStrike Germ-Zapping Robots Destroy Superbugs Before They Harm Hospital Patients

Altan Pharma Announces Licensing Agreement for Generic of Antifungal Agent Caspofungin

Altan Pharma Announces the Launch of Linezolid 2mg/ml Solution for Infusion in Spain

Melinta Therapeutics to Present at BioCentury Future Leaders Conference

Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis

Novan’s Phase 2b Results with SB204 to be Presented at AAD

Infection Rates Decline at Florida Hospital after Xenex Germ-Zapping Robots Used for Room Disinfection; Hospital Estimates Xenon Light Robots Helped Hospital Avoid 58 Infections & Save $730,000

Novan Announces First Patient Dosed in Phase 3 Program for SB204

Melinta Therapeutics Appoints John Temperato President and Chief Operating Officer

Novan Announces Robert A. Ingram as Chairman

Kymab Succeeds in Revoking Regeneron’s UK VelocImmune® Patents

Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma

Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab

3D4Medical announces 70 new jobs over next 18 months

Viamet to Present at the 3rd Annual Dermatology Summit

Kymab and MD Anderson Announce Strategic Partnership in Immuno-Oncology Research & Development

Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia

Immunocore and GlaxoSmithKline Select First ImmTAC Clinical Candidate in Discovery Collaboration

Melinta Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference

Immunocore expands its senior management team and opens US Office

Poseida Therapeutics Announces Series A Financing

Immunocore Wins Biotech of the Year at the SCRIP Awards 2015

EMBA Medical™ Limited Cleared to Market Hourglass™ Peripheral Embolization Plug in New Zealand

Xenex Germ-Zapping Robot™ Destroys Ebola Virus & Anthrax Spores in New Study Performed at Texas Biomed Biosafety Level 4 Lab

Serenus Biotherapeutics to Launch Xenex UV Disinfection Robot at IPNET-K Conference 2015 in Naivasha, Kenya

Xenex Awarded Premier, Inc. Group Purchasing Contract to Offer Germ-Zapping Robot™ Room Disinfection Technology to Premier Member Hospitals

Viamet Appoints Dr. Volker Herrmann as Chief Commercial Officer

Surgical Site Infections Decrease 100% after Trinity Medical Center Implements Infection Control Bundle with Xenex Germ-Zapping Robots for Room Disinfection

Serenus Biotherapeutics Enters Agreement with Hanmi Pharmaceutical to Bring Combination Therapy to Treat Growing Problem of Hypertension in Africa

Viamet Appoints Dr. Oren Cohen as Chief Medical Officer

Serenus Biotherapeutics Opens East African Regional Office in Nairobi, Kenya

Melinta Therapeutics Presents Complete Delafloxacin Results from Phase 3 Study in Patients with Acute Bacterial Skin and Skin Structure Infections at ID Week

Novan Appoints Chief Financial Officer and Chief Commercial Officer to Leadership Team

Serenus Biotherapeutics President Dr. Skhumbuzo Ngozwana to Participate in World Health Summit in Berlin

Novan Announces Successful Phase 2b Clinical Trial Results with SB204 for the Treatment of Acne Vulgaris

Melinta Therapeutics Demonstrates Potency of Delafloxacin against Bacteria Associated with Respiratory Tract Infections

Serenus Biotherapeutics Partners With Xenex to Bring Xenex Disinfection Robots to Africa

FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis

Viamet to Present at ICAAC/ICC 2015

Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme

3D4Medical unveil preview of revolutionary 3D ‘Complete Anatomy Series’

Immunocore Ranked No 1 South East Company in the Annual Sunday Times Hiscox Tech Track 100

The Sunday Times Hiscox Tech Track recognises Kymab as ‘One to Watch’

The Royal Society publishes a video case study on Immunocore

Xenex Signs Agreement with HealthTrust; Germ-Zapping Robots™ Added to the HealthTrust Portfolio

Viamet and Mycoses Study Group Education & Research Consortium Establish Collaboration to Advance a Novel Therapy for Cryptococcal Meningitis

Hatteras Venture Partners Announces First Closing of HVP V

Viamet to Present at American Chemical Society National Meeting

Nicklaus Children’s Hospital Acquires Xenex Germ-Zapping Robot to Enhance Patient Safety

Immunocore announces Fidelity’s Participation in $320M Financing

EMBA Medical Awarded CE Certificate for Hourglass™ Peripheral Embolization Plug

Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting

Immunocore secures $320 million (£205 million) in Europe’s Largest Private Life Sciences Financing

Serenus Biotherapeutics Names Renowned Industry Leader Skhumbuzo Ngozwana, M.D., as President

Two New Studies Show Decrease in Hospital Acquired Infections after Xenex Germ-Zapping Robots Used for Room Disinfection

Xenex Offers Industry’s First HAI Reduction Guarantee; Multiple Hospitals Report Decrease in Infection Rates When Using Xenex Germ-Zapping Robots for Room Disinfection

Former Elan CEO Takes Helm of Expanded Serenus Biotherapeutics Board of Directors

Novan presentation at the 23rd World Congress of Dermatology

Viamet Announces Awarding of Department of Defense Grant

Viamet Announces NIH Grant for Compounds Directed at Valley Fever

GAO Affirms VA Contract for Mercury-Free UV Disinfection System, Milwaukee VA Hospital Orders Xenex Full-Spectrum™ Germ-Zapping Robots™

Kymab secures US$90 million funding

Viamet to Provide Update on Novel Antifungal Programs at ECCMID 2015